Posts Tagged ‘ticagrelor’

July 28th, 2010

FDA Cardiorenal Advisory Panel Recommends Ticagrelor Approval

The Cardiovascular and Renal Drugs Advisory Committee recommended today that ticagrelor (Brilinta, AstraZeneca) be approved for the treatment of STEMI and NSTEMI patients intended to be managed both invasively and medically. The committee spent most of the day trying to sort through the confusing finding in the pivotal PLATO trial that U.S. patients, unlike patients […]